Result: At 48 week of TDF therapy, the frequencies of
rtM204I,
rtL80I,
sS45A,
sT118V,
sW196L and
sA128V continued to be significantly reduced from baseline in responders, although an increase in frequency of the substitution
rtV278I was noted in the HBV clones of the responders during this observational period (Table 5).